Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + adefovir dipivoxil
- Development stage
- Preclinical
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Emtricitabine + adefovir dipivoxil is an investigational combination of two antiviral agents, both classified as nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs/ntRTIs). Emtricitabine inhibits viral reverse transcriptase by acting as a cytidine analog, while adefovir dipivoxil is an oral prodrug of adefovir, an acyclic nucleotide analog of adenosine monophosphate. Adefovir is phosphorylated intracellularly to its active form and inhibits hepatitis B virus (HBV) DNA polymerase by competing with the natural substrate and causing DNA chain termination after incorporation into viral DNA[1][5]. This combination has been studied preclinically for enhanced antiviral activity against chronic hepatitis B infection and to help manage drug resistance in HBV therapy[5]. The primary indication under investigation is chronic hepatitis B.
- Other names
- FTC + ADVemtricitabine plus adefovir dipivoxil
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)POLG (Mitochondrial DNA polymerase gamma)
Beyond the preview
Go deeper on emtricitabine + adefovir dipivoxil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + adefovir dipivoxil.